NCT06246227Active, not recruiting
ctDNA for Early Detection of Recurrence in Melanoma
The Value of Circulating Tumour DNA in Early Detection of Recurrence of Melanoma
Source: ClinicalTrials.gov · Last updated 24 Apr 2026
Brief summary (registry, in English)
This study examines circulating tumor DNA (ctDNA) as a biomarker for early detection of recurrence in high-risk patients, following treatment of primary melanoma. The hypothesis is that ctDNA can provide accurate detection of recurrence or metastasis, at the time of or earlier than current methods, leading to improved management and hopefully prognosis, based on earlier detection.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 467 (actual)
- First submitted
- 30 Jan 2024
- Start date
- 1 Jul 2019
- Primary completion date
- 6 Oct 2027
- Lead sponsor
- Herlev and Gentofte Hospital
- Diseases
- Melanoma
- NCT number
- NCT06246227
What you commit to
- Study type: Observational
- Participants enrolled: 467
- From 1 Jul 2019 to the primary completion date, 6 Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous history of melanoma
Other
- Pregnancy
Who the study is looking for
- Follow-up for Primary Melanoma, Stages IIB to III and Resected Stage IV
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Detp. of Pastic and Reconstructive Surgery, Herlev Hospital Coordinator of this site? Confirm its status | Herlev | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.